CClinicalTrials.gg
Status unknownNCT03385187Updated Mar 21, 2019

Prospective Validation Study of a Novel Type IV Home Sleep Apnea Test

An interventional study of NightOwl HSAT in Sleep Apnea, sponsored by Ectosense NV. Status unknown at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-21.

Sponsored by Ectosense NV · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Prospective validation study of the NightOwl, a Type IV home sleep apnea test (HSAT), compared to a traditional Type I and a Type IV sleep monitor.

Read the detailed description

The purpose of this prospective validation study is the evaluation of the accuracy of the NightOwl HSAT to derive parameters relevant for the diagnosis of sleep apnea. The NightOwl HSAT comprises a finger or forehead mounted sensor and an automated analytics software. The sensor measures double-wavelength photo-plethysmography and accelerometry. The analytics software automatically interprets the sensor data and derives a measure of sympathetic activation of the autonomic nervous system, oxygen saturation, instantaneous pulse rate and activity. For each patient in the cohort, the AHI derived by the NightOwl will be compared to that of the Type I sleep monitor (in-lab PSG), which will acquire data simultaneously during the diagnostic night of the patient referred to the sleep lab for a polysomnography. On a randomly selected subset of patients, a Type IV sleep monitor will additionally be applied for comparison of its automated AHI derivation to that of the NightOwl.

02

Conditions studied

  • Sleep Apnea
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Indication for a sleep study

Exclusion criteria

Exclusion Criteria:

  • Mentally disabled people
  • Known allergy to Plexiglas (PMMA) or other acrylates
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Other
    NightOwl HSAT

    Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.

    Device: NightOwl HSAT

Interventions

  • DeviceNightOwl HSAT

    Patient wears the NightOwl sensor device

05

What researchers measure

Primary outcomes

  1. Apnea-Hypopnea Index (AHI)

    Comparison of the AHI derived from the NightOwl HSAT to that of the Type I and Type IV sleep monitors

    Time frame: At the time of the diagnostic night

Secondary outcomes

  1. Sleep-wake discrimination

    Comparison of the sleep-wake discrimination derived from the NightOwl HSAT to that of the Type I and Type IV sleep monitors

    Time frame: At time of the diagnostic night

06

Study locations

1 of 1 sites recruiting
  • Ziekenhuis Oost-Limburg
    Genk, Limburg 3600, Belgium
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03385187
Lead sponsor
Ectosense NV
Collaborators
Ziekenhuis Oost-Limburg
Responsible party
Sponsor
First posted
Dec 28, 2017
Start date
Jun 29, 2017
Primary completion
Sep 15, 2019 (estimated)
Completion
Dec 15, 2019 (estimated)
Last update
Mar 21, 2019

Study contacts

Duarte Mendes de Almeida, Ir.
Contact
d.mdealmeida@ectosense.com
+32 468 17 27 89
Duarte Mendes de Almeida, Ir.
study director · Ectosense NV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion